2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
2021
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening
2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
2019
Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen
2018
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data
Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models
2017
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
2016
Validation of the National Cancer Registration and Analysis Service prostate cancer registry with data from the CAP study
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
Validation of the Hospital Episode Statistics Outpatient Dataset in England
2015
Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer
Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
2014
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial
2013
“Let’s get the best quality research we can”: public awareness and acceptance of consent to use existing data in health research: a systematic review and qualitative study
